# Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 Diabetes

Study · id `cardio:ct-nct05990205` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05990205](<https://clinicaltrials.gov/study/NCT05990205>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05990205

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 437 participants.

## Technical summary

Registry record NCT05990205. Randomized; no masking; primary purpose prevention. Start 2018-04-17 (actual); primary completion 2023-12-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 437 participants (enrolled count; ClinicalTrials.gov record NCT05990205, source copy `cardio:ctgov-nct05990205-2024-05-24`, retrieved 2026-11-18)
- Started: 2018-04-17 (actual) (ClinicalTrials.gov record NCT05990205, source copy `cardio:ctgov-nct05990205-2024-05-24`, retrieved 2026-11-18)
- Primary completion: 2023-12-20 (actual) (ClinicalTrials.gov record NCT05990205, source copy `cardio:ctgov-nct05990205-2024-05-24`, retrieved 2026-11-18)
- Completion: 2024-03-01 (actual) (ClinicalTrials.gov record NCT05990205, source copy `cardio:ctgov-nct05990205-2024-05-24`, retrieved 2026-11-18)
- Countries: Mexico (ClinicalTrials.gov record NCT05990205, source copy `cardio:ctgov-nct05990205-2024-05-24`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05990205-2024-05-24`, retrieved 2026-11-18)

## The registry's words

- Brief title: Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 Diabetes
- Acronym: PRED2
- Condition: PreDiabetes
- Intervention (Drug): Life Style Intervention + Metformin
- Intervention (Behavioral): Life Style Intervention
- Lead sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)

## Provenance

Content hash: cf8c980e1629a64d0ef8a37d1c58a9dc17ec93e595477752410b4aa21ddfe397
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
